OmniTier Storage provides on-premise genomic analysis appliances that utilize AI-based variant interpretation to enhance the accuracy and speed of diagnosing rare genetic diseases. By automating secondary analysis and supporting multiple sequencing technologies, the platform enables researchers and clinicians to efficiently implement custom methodologies while maintaining control over patient data and reducing costs.
Funding
$28.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The analysis of genomic data for rare disease diagnosis is often slow and inaccurate, requiring specialized bioinformatics expertise and significant computational resources. Existing solutions can be costly, lack scalability, and may not adequately support custom methodologies or maintain control over sensitive patient data.
Solution
OmniTier provides on-premise genomic analysis appliances that streamline and enhance the accuracy of rare genetic disease diagnosis. The platform automates secondary analysis and variant interpretation using AI, reducing the time required from days to minutes. It supports multiple sequencing technologies, including Illumina, MGI Tech, Oxford Nanopore Technology, and PacBio, enabling researchers and clinicians to implement custom methodologies efficiently. The appliances are designed to scale from a few exomes to thousands of whole genomes, while ensuring data security and reducing costs associated with large data storage and analysis.
Target Audience
The primary target audience includes researchers, clinicians, bioinformaticians, sequencing service providers, and pharmaceutical companies involved in clinical diagnostics, screening, and genomic research.
Features
- On-premise appliances for lower analysis costs and greater control over patient data
- Support for Illumina, MGI Tech, Oxford Nanopore Technology, and PacBio sequencing platforms
- Includes both a proprietary (Novos) and standard (GATK) variant caller for SNPs, indels, structural variants, and CNVs
- AI-powered automation reduces secondary analysis and variant interpretation time
- Scalable infrastructure to support analysis from a few exomes to thousands of whole genomes
- End-to-end, easy-to-use, built-in analysis workflows designed for researchers, clinicians, and bioinformaticians